These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29185086)

  • 1. Interstitial lung disease in South Africans with systemic sclerosis.
    Ashmore P; Tikly M; Wong M; Ickinger C
    Rheumatol Int; 2018 Apr; 38(4):657-662. PubMed ID: 29185086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.
    Hoa S; Bernatsky S; Steele RJ; Baron M; Hudson M;
    Rheumatology (Oxford); 2020 May; 59(5):1108-1117. PubMed ID: 31535689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
    Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
    Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study.
    Wangkaew S; Euathrongchit J; Wattanawittawas P; Kasitanon N; Louthrenoo W
    Mod Rheumatol; 2016 Jul; 26(4):588-93. PubMed ID: 26561397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
    Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
    Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
    Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
    Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis.
    Campochiaro C; Hoffmann-Vold AM; Avouac J; Henes J; de Vries-Bouwstra J; Smith V; Siegert E; Airò P; Oksel F; Pellerito R; Vanthuyne M; Pozzi MR; Inanc M; Sibilia J; Gabrielli A; Distler O; Allanore Y;
    Rheumatology (Oxford); 2023 Jul; 62(7):2483-2491. PubMed ID: 36413079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.
    Qiu M; Nian X; Pang L; Yu P; Zou S
    Int J Rheum Dis; 2021 Dec; 24(12):1449-1459. PubMed ID: 34418313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of patients with systemic sclerosis who develop interstitial lung disease].
    Fajardo-Hermosillo LD; Ocampo-Torres MC; Rodríguez-Silverio J
    Rev Med Inst Mex Seguro Soc; 2023 Oct; 61(Suppl 3):S363-S371. PubMed ID: 37934671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort.
    Jung M; Bonner A; Hudson M; Baron M; Pope JE;
    Scand J Rheumatol; 2014; 43(3):217-20. PubMed ID: 24650305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.
    Chong WH; Saha BK; Beegle S
    Am J Med Sci; 2023 Feb; 365(2):198-204. PubMed ID: 35276077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
    Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
    Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
    Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
    Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
    Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
    Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
    J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease.
    Mango RL; Matteson EL; Crowson CS; Ryu JH; Makol A
    Lung; 2018 Aug; 196(4):409-416. PubMed ID: 29785507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.